Orthocell Reports Record October Sales for Remplir Nerve Wrap in U.S. Market
Orthocell Ltd (ASX: OCC) has announced its strongest monthly sales performance in the United States since the launch of its collagen nerve wrap, Remplir™. In October 2026, the company sold 92 units, generating AU$279,000 in revenue. This represents an 84% increase compared to the average monthly sales of 50 units recorded during Q1 FY27. The surge in revenue is attributed to increased surgeon adoption, higher repeat utilization rates, and expanded hospital access across key U.S. markets. Management noted that the commercial groundwork laid over the past year is now translating into tangible financial results as their distributor network expands.
Tickers: $OCC
Topics: commercial performance market expansion medical device sales revenue growth
Read the full article at PR Newswire
Part of the story Orthocell Reports Record October Sales for Remplir Nerve Wrap in U.S. Market (3 articles)